《大行報告》匯豐研究下調中國建築(03311.HK)目標價至10.4元 評級「買入」
匯豐環球研究發表報告指,中國建築(03311.HK)今年第三季收入按年增長15.6%,淨利潤按年增長21%,符合預期,管理層對達成全年目標有信心,預期盈利增長幅度可達雙位數。
該行指出,香港新一份施政報告提出建設北部都會區,計劃推進或較預期快,而中國建築擁有預製組件的技術優勢,將可快速獲取市場份額,預期發展規劃將成爲中國建築未來幾年的催化劑。
但考慮到成本上升,該行將中國建築2021至2023年盈利預測下調均3%,相應將目標價由10.7元輕微下調至10.4元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.